The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma

• Published in: Biomedicines Vol. 8; no. 12; p. 565
• Main Authors: Ciernikova, Sona, Novisedlakova, Maria, Cholujova, Danka, Stevurkova, Viola, Mego, Michal
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 03.12.2020; MDPI
• Subjects: Adenocarcinoma; Biomarkers; Cancer therapies; cancer treatment; Chemotherapy; Clinical trials; Deoxyribonucleic acid; DNA; Ethnicity; Genomes; immune suppression; Immune system; Immunological tolerance; Medical prognosis; Metastasis; Microbiomes; Microbiota; microbiota modulation; Mutation; Pancreas; Pancreatic cancer; pancreatic ductal adenocarcinoma (PDAC); pancreatic microbiome; Review; Solid tumors; tumor microenvironment; Tumorigenesis; Tumors; cancer treatment; microbiota modulation; tumor microenvironment; pancreatic ductal adenocarcinoma (PDAC); immune suppression; pancreatic microbiome
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines8120565

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignant tumors due to the absence of biomarkers for early-stage detection and poor response to therapy. Since mounting evidence supports the role of microbiota composition in tumorigenesis and cancer treatment, the link between microbiome and PDAC has been described. In this review, we summarize the current knowledge regarding the impact of the gut and oral microbiome on the risk of PDAC development. Microenvironment-driven therapy and immune system interactions are also discussed. More importantly, we provide an overview of the clinical trials evaluating the microbiota role in the risk, prognosis, and treatment of patients suffering from PDAC and solid tumors. According to the research findings, immune tolerance might result from the microbiota-derived remodeling of pancreatic tumor microenvironment. Thus, microbiome profiling and targeting represent the potential trend to enhance antitumor immunity and improve the efficacy of PDAC treatment.